[1]韦 奇,高振轩,高 阳,等.他汀类药物联合抗血小板药物降低冠状动脉搭桥术后血管再狭窄的研究[J].医学信息,2019,32(20):40-44.[doi:10.3969/j.issn.1006-1959.2019.20.012]
　WEI Qi,GAO Zhen-xuan,GAO Yang,et al.Study of Statins Combined with Antiplatelet Drugs to Reduce Vascular Restenosis after Coronary Artery Bypass Grafting[J].Journal of Medical Information,2019,32(20):40-44.[doi:10.3969/j.issn.1006-1959.2019.20.012]
点击复制

他汀类药物联合抗血小板药物降低冠状动脉搭桥术后血管再狭窄的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年20期
页码:
40-44
栏目:
综述
出版日期:
2019-10-15

文章信息/Info

Title:
Study of Statins Combined with Antiplatelet Drugs to Reduce Vascular Restenosis after Coronary Artery Bypass Grafting
文章编号:
1006-1959（2019）20-0040-05
作者:
韦 奇1; 高振轩1; 高 阳1; 任京媛2
（1.首都医科大学2015级临床医学专业，北京 100069；2.首都医科大学附属北京安贞医院高血压科，北京 100025）
Author(s):
WEI Qi1; GAO Zhen-xuan1; GAO Yang1; REN Jing-yuan2
(1.Major in Clinical Medicine,Grade 2015,Capital Medical University,Beijing 100069,China;2.Department of Hypertension,Beijing Anzhen Hospital,Capital Medical University,Beijing 100025,China)
关键词:
冠状动脉旁路移植术; 血管再狭窄; 抗血小板药物; 他汀类药物
Keywords:
Coronary artery bypass grafting; Vascular restenosis; Antiplatelet drugs; Statins
分类号:
R543
DOI:
10.3969/j.issn.1006-1959.2019.20.012
文献标志码:
A
摘要:
冠状动脉旁路移植术（CABG）是治疗冠心病有效手段之一，但是其术后易发生桥静脉再狭窄甚至闭塞，发生复发性心绞痛、心肌梗死以及再次血运重建的风险增加。抗血小板药物和他汀类药物是临床提高桥血管通畅率的常用药物，抗血小板药物能减少早期的血栓形成，他汀类药物能够延缓中期的内膜增厚和晚期的粥样斑块的形成。本文就联合使用抗血小板药物和他汀类药物降低CABG术后血管再狭窄的研究作一综述，并对综合治疗CABG术后血管再狭窄的方法进行展望。
Abstract:
Coronary artery bypass grafting (CABG) is one of the effective methods for the treatment of coronary heart disease, but it is prone to restenosis or even occlusion of the bridge vein, and the risk of recurrent angina pectoris, myocardial infarction and revascularization is increased. Antiplatelet drugs and statins are commonly used drugs to improve the patency rate of bridge blood vessels. Antiplatelet drugs can reduce early thrombosis. Statins can delay the formation of metaphase intimal thickening and advanced atheroma. This article reviews the use of antiplatelet drugs and statins to reduce vascular restenosis after CABG, and prospects for the comprehensive treatment of vascular restenosis after CABG.

参考文献/References:

[1]Kim LK,Looser P,Swaminathan RV,et al.Outcomes in patients undergoing coronary artery bypass graft surgery in the United States based on hospital volume,2007 to 2011[J].J Thorac Cardiovasc Surg,2016,151(6):1686-1692. [2]Tranbaugh RF,Schwann TA,Swistel DG,et al.Coronary Artery Bypass Graft Surgery Usingthe Radial Artery,Right Internal Thoracic Artery,orSaphenous Vein as theSecondConduit[J].Annals of Thoracic Surgery,2017,104(2):S0003497516316198. [3]Yamasaki M,Deb S,Tsubota H,et al.Comparison of Radial Artery and Saphenous Vein Graft Stenosis More Than 5 Years After Coronary Artery Bypass Grafting[J].Ann Thorac Surg,2016,102(3):712-719. [4]YamaneY,Uchida N,Okubo S,et al.Impact of the size mismatch between saphenous vein graft and coronary artery on graft patency[J].General Thoracic&Cardiovascular Surgery,2016,65(1):1-7. [5]刘巍,周玉杰,刘字扬,等.静脉桥病变的介入治疗及临床预后的观察[A]//第七届北京五洲心血管病研讨会论文集[C].首都医科大学附属北京安贞医院,2013. [6]Harskamp RE,Lopes RD,Baisden CE,et al.Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery[J].Annals of surgery,2013,257(5):824-833. [7]Kim FY,Marhefka G,Ruggiero NJ,et al.Saphenous Vein Graft Disease:,Review of Pathophysiology, Prevention,and Treatment[J].Cardiology in Review,2013,21(2):101-109. [8]Tseng CN,Karl?觟f E,Chang YT,et al.Contribution of Endothelial Injury and Inflammation in Early Phase to Vein Graft Failure:The Causal Factors Impact on the Development of Intimal Hyperplasia in Murine Models[J].PloS One,2014,9(6):e98904. [9]Longchamp A,Alonso F,Dubuis C,et al.The use of external mesh reinforcement to reduce intimal hyperplasia and preserve the structure of human saphenous veins[J].Biomaterials,2014,35(9):2588-2599. [10]Taggart DP,Ben Gal Y,Lees B,et al.A Randomized Trial of External Stenting for Saphenous Vein Grafts in Coronary Artery Bypass Grafting[J].The Annals of Thoracic Surgery,2015,99(6):2039-2045. [11]Pere kB,Malinska A,Misterski M,et al.Preexisting high expression of matrix metalloproteinase-2 in tunica media of saphenous vein conduits is associated with unfavorable long-term outcomes after coronary artery bypass grafting[J].Bio Med Research International,2013(3):730721. [12]Ezhov MV,Afanasieva OI,Il"Ina LN,et al.Association of lipoprotein(a)level with short- and long-term outcomes after CABG:The role of lipoprotein apheresis[J].Atherosclerosis Supplements,2017(30):187-192. [13]Yahagi K,Kolodgie FD,Fran kD,et al.Pathophysiologyof native coronary,vein graft,and in-stent atherosclerosis[J].Nature Reviews Cardiology,2015,13(2):79. [14]Yanagawa B,Algarni KD,Khaled D,et al.Clinical, biochemical, and genetic predictors of coronary artery bypass graft failure[J].Journal of Thoracic&Cardiovascular Surgery,2014,148(2):515-520. [15]Balogh E,Darago A,Csapo K,et al.Homocysteine increases the risk of long term coronary artery saphenous venous graft progression[J].European Heart Journal,2013,34(1):3115. [16]Wang B,Yamamoto MH,Nand P,et al.Long-term changes in plaque burden and vessel remodeling in saphenous vein grafts:insights from serial intravascular ultrasound[J].Coronary artery disease,2016,27(6):523-527. [17]程斌,穆军升.冠状动脉旁路移植手术后的血管用药[J].中华胸心血管外科杂志,2013,29(5):311-314. [18]Jing-Jing SU,Liu HY.Research Progress in Saphenous Vein Graft Restenosis after Coronary Artery Bypass Grafting[J].Chinese Journal of Clinical Thoracic&Cardiovascular Surgery,2013. [19]Hlatky MA,Solomon MD,Shilane D,et al.Use of Medications for Secondary Prevention After Coronary Bypass Surgery Compared With Percutaneous Coronary Intervention[J].Journal of the American College of Cardiology,2013,61(3):295-301. [20]Hage A,Voisine P,Erthal F,et al.Eight-Year Follow-up of the Clopidogrel After Surgery for Coronary Artery Disease(CASCADE)Trial[J].The Journal of Thoracic and Cardiovascular Surgery, 2018,155(1):212-222. [21]Deo SV,Dunlay SM,Shah IK,et al.Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting:Is There Any Benefit?A Systematic Review and Meta-Analysis[J].Journal of Cardiac Surgery,2013,28(2):109-116. [22]Ebrahimi R,Gupta S,Carr BM,et al.Comparison of Outcomes and Costs Associated with Aspirin+/- Clopidogrel after Coronary Artery Bypass Grafting[J].American Journal of Cardiology,2018,121(6):709-714. [23]Levine GN,Glenn N,Bates ER,et al.2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease[J].J Thorac Cardiovasc Surg,2016,152(5):1243-1275. [24]Poston RS,Gu J,Brown M,et al.Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting[J].Journal of Thoracic&Cardiovascular Surgery,2006,131(1):122-130. [25]Floyd CN,Ferro A.Mechanisms of aspirin resistance[J].Pharmacology and Therapeutics,2014,141(1):69-78. [26]王学忠,龚晓璇,朱甜甜,等.联合氯吡格雷和阿司匹林抗血小板治疗对非体外循环冠状动脉旁路移植术后患者阿司匹林抵抗的影响[J].中国医学科学院学报,2013,35(5):495-502. [27]吴文波,吴明营,周自强,等.阿司匹林剂量对非体外循环下冠状动脉旁路移植术后获得性阿司匹林抵抗的影响[J].中华临床医师杂志(电子版),2013,7(13):49-52. [28]Gasparovic H,Petricevic M,Kopjar T,et al Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting[J].Am J Cardiol,2014(113):1660-1667. [29]王秀珠,范国峰.经皮冠状动脉介入治疗术后抗血小板治疗依从性调查分析[J].中国全科医学,2010,13(31):3570-3571. [30]Nocerino AG,Achenbach S,Taylor AJ.Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting[J].American Journal of Cardiology,2013,112(10):1576-1579. [31]Une D,Al-Atassi T,Kulik A,et al.Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery Disease(CASCADE)randomized trial[J].Circulation,2014,130(1):12-18. [32]Ohman EM,Roe MT,Matthew T,et al.Clinically significant bleeding with low-dose rivaroxaban versus aspirin,in addition to P2Y12 inhibition,in acute coronary syndromes(GEMINI-ACS-1):a double-blind,multicentre,randomised trial[J].Lancet,2017,389(10081):1799-1808. [33]Yahagi K,Kolodgie FD,Otsuka F,et al.Pathophysiologyof native coronary,vein graft,and in-stent atherosclerosis[J].Nature Reviews Cardiology,2016,13(2):79-98. [34]Kang S,Liu Y,Liu XB.Effects of Aggressive Statin Therapy on Patients With Coronary Saphenous Vein Bypass Grafts:A Systematic Review and Meta-Analysis of Randomized,Controlled Trials[J].Clinical Therapeutics,2013,35(8):1125-1136. [35]Lazar HL.Role of statin therapy in the coronary bypass patient[J].Annals of Thoracic Surgery,2004,78(2):730-740. [36]Shah SJ,Waters DD,Barter P,et al.Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery[J].Journal of the American College of Cardiology,2008,51(20):1938-1943. [37]Kulik A,Abreu AM,Boronat V,et al.Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG:Rationale and design of the ACTIVE(Aggressive Cholesterol Therapy to Inhibit Vein Graft Events)randomized controlled trial(NCT01528709)[J].Contemporary Clinical Trials,2017(59):98-104. [38]程斌,穆军升,张健群,等.冠状动脉旁路移植术后使用负荷剂量他汀类药物中长期疗效的Meta分析[J].中华胸心血管外科杂志,2015,31(11):679-682,701. [39]Musial J,Undas A,Undas R,et al.Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels[J].Thrombosis&Haemostasis,2001,85(2):221-225. [40]Xianghua F,Qian W,Yanbo W,et al.Influence on the platelet function of different statins combined with loading dose clopidogrel in patients with acute coronary syndrome[J].Heart,2010,96(3):A194-A195. [41]Nakamura K,Masuda H,Kariyazono H,et al.Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting[J].Cytokine,2006,36(5-6):201-210. [42]Gupta RK,Bapuraj JR.Prognostic indices for cerebral venous thrombosis on CT perfusion:A prospective study[J].European Journal of Radiology,2014,83(1):185-190. [43]何中伏,李国瑞,段宪云.阿司匹林联合他汀类药物治疗脑血栓的疗效及对颈动脉斑块的影响分析[J].中国合理用药探索,2017,14(7):13-15,19. [44]吴菁华.他汀类联合心血管药物治疗心血管疾病的临床效果分析[J].当代医学,2014(3):151-152. [45]耿凡龙,张霞.强化他汀联用抗血小板药物对支架植入术后再狭窄防治效果的观察[J].中西医结合心血管病电子杂志,2019,7(1):61-62.

相似文献/References:

[1]马洪俊.冠状动脉左主干病变的治疗研究[J].医学信息,2019,32(14):42.[doi:10.3969/j.issn.1006-1959.2019.14.015]
　MA Hong-jun.Study on the Treatment of Left Main Coronary Artery Disease[J].Journal of Medical Information,2019,32(20):42.[doi:10.3969/j.issn.1006-1959.2019.14.015]
[2]周玉娟,王 磊.非体外循环冠状动脉旁路移植术后早期认知功能障碍的临床研究[J].医学信息,2021,34(22):45.[doi:10.3969/j.issn.1006-1959.2021.22.012]
　ZHOU Yu-juan,WANG Lei.Clinical Study on Postoperative Cognitive Dysfunction After Off-pump Coronary Artery Bypass Grafting[J].Journal of Medical Information,2021,34(20):45.[doi:10.3969/j.issn.1006-1959.2021.22.012]
[3]尚 丹,张紫娟.全程吸入不同浓度七氟烷对冠状动脉旁路移植术患者心肌保护作用及炎症细胞因子的影响[J].医学信息,2022,35(19):99.[doi:10.3969/j.issn.1006-1959.2022.19.027]
　SHANG Dan,ZHANG Zi-juan.Effects of Inhalation of Different Concentrations of Sevoflurane on Myocardial Protection and Inflammatory Cytokines in Patients Undergoing Coronary Artery Bypass Grafting[J].Journal of Medical Information,2022,35(20):99.[doi:10.3969/j.issn.1006-1959.2022.19.027]

更新日期/Last Update: 2019-10-15